-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Follicular lymphoma (FL) is an indolent lymphoma in most patients who are sensitive to chemotherapy or immunochemotherapy (IC), and although overall survival in patients during the rituximab era improves, FL is considered an incurable disease
FL is a more aggressive histological transformation (tFL), usually to diffuse large B-cell lymphoma (DLBCL), which is an important clinical event associated with adverse outcomes with an annual risk of histological transformation (HT) of 2% to 3%
Scholars in Western countries have described in detail the demographics, baseline disease characteristics, initial treatment strategies, and outcomes of FL patients, while data on FL patients in China are limited, especially in the absence of single-center large-sample studies
Results of the study